MiR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1286-1296

  Zhu, Xiaolan ^a,b   Li, Yuefeng ^b,c   Xie, Chanjuan ^b   Yin, Xinming ^a   Liu, Yueqin ^a   Cao, Yuan ^b   Fang, Yue ^b   Lin, Xin ^a   Xu, Yao ^a   Xu, Wenlin ^a,b   Shen, Huiling ^d   Wen, Jian ^a  

^a The Fourth People's Hospital of Zhenjiang   (China)

^b JIANGSU UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^d AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Cdk6; miR 145; P gp; pRb; Sp1

Indexed keywords

BINDING PROTEIN; CYCLIN DEPENDENT KINASE 6; MICRORNA 145; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PRB PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL LEVEL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SENSIBILITY; SIGNAL TRANSDUCTION;

CDK6; MIR-145; P-GP; PRB; SP1;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICRORNAS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904055032     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28774     Document Type: Article

References (43)

1. Pellicciotta I, Yang CP, Venditti CA, et al. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int 2013; 13: 33.
2. Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012; 130: 1787-97.
3. Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011; 17: 1591-602.
4. Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer cell 2013; 23: 186-99.
5. Huh JH, Kim TH, Kim K, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 2013; 109: 452-61.
6. Guo CJ, Pan Q, Li DG, et al. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol 2009; 50: 766-78.
7. Ouyang YB, Lu Y, Yue S, et al. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2012; 12: 213-19.
8. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007; 104: 13513-18.
9. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-8.
10. Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010; 79: 817-24.
11. To KK, Zhan Z, Litman T, et al. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008; 28: 5147-61.
12. Xiang Y, Ma N, Wang D, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014; 33: 378-86.
13. Chan M, Liaw CS, Ji SM, et al. Identification of circulating MicroRNA signatures for breast cancer detection. Clin Cancer Res 2013; 19: 4477-87.
14. Xu Q, Liu LZ, Qian X, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40: 761-74.
15. Shi B, Sepp-Lorenzino L, Prisco M, et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582-90.
16. Cho WC, Chow AS, Au JS,. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011; 8: 125-31.
17. Gramantieri L, Fornari F, Ferracin M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-81.
18. Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125: 345-52.
19. Amaral FC, Torres N, Saggioro F, et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 2009; 94: 320-3.
20. Akao Y, Nakagawa Y, Kitade Y, et al. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-20.
21. Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer 2013; 23: 673-9.
22. Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32: 772-8.
23. Zhang J, Guo H, Zhang H, et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 2011; 117: 86-95.
24. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-12.
25. Zhang J, Guo H, Qian G, et al. MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer 2010; 9: 211.
26. Sachdeva M, Mo YY,. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70: 378-87.
27. Xu N, Papagiannakopoulos T, Pan G, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647-58.
28. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 9: 374.
29. Zhan M, Yu D, Liu J, et al. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 2005; 280: 4825-33.
30. Previdi S, Malek A, Albertini V, et al. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 2010; 118: 182-8.
31. Hu Z, Jin S, Scotto KW,. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000; 275: 2979-85.
32. Marconett CN, Sundar SN, Tseng M, et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis 2011; 32: 1315-23.
33. Cram EJ, Liu BD, Bjeldanes LF, et al. Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem 2001; 276: 22332-40.
34. Bauer JA, Ye F, Marshall CB, et al. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 2010; 12: R41.
35. Zhu H, Dougherty U, Robinson V, et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res 2011; 9: 960-75.
36. Zhu X, Li Y, Shen H, et al. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett 2013; 587: 73-81.
37. Zhu X, Li Y, Shen H, et al. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin 2013; 45: 80-6.
38. Wang YC, Juric D, Francisco B, et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 2006; 45: 365-74.
39. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.
40. Ye G, Fu G, Cui S, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011; 124: 359-68.
41. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68: 10307-14.
42. Cittelly DM, Dimitrova I, Howe EN, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012; 11: 2556-65.
43. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-44.